

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/130318 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61P 13/12 (2006.01)

(21) International Application Number:

PCT/IB2021/061926

(22) International Filing Date:

17 December 2021 (17.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/127,849 18 December 2020 (18.12.2020) US
63/213,973 23 June 2021 (23.06.2021) US

(71) Applicant: **MOMENTA PHARMACEUTICALS, INC.**
[US/US]; 301 Binney Street, Cambridge, MA 02142 (US).

(72) Inventors: **KURTAGIC, Elma**; 301 Binney Street, Cambridge, Massachusetts 02142 (US). **MEADOR, III, James W.**; 301 Binney Street, Cambridge, Massachusetts 02142 (US). **BENEDUCE, Christopher**; 301 Binney Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: **FRANK, Eve L.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(88) Date of publication of the international search report:

04 August 2022 (04.08.2022)

(54) Title: ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1

(57) Abstract: The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 ($\alpha 11\beta 1$), as well as methods of making and using such antibodies.

WO 2022/130318 A3